{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:32:16Z","timestamp":1794562336437,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpet.2026.105025","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:59:43Z","timestamp":1788389983000},"page":"105025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational pharmacokinetic\/pharmacodynamic modeling to inform target concentration and dose projection of a novel selective estrogen receptor degrader (SIM0270) for early clinical development"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9476-0312","authenticated-orcid":false,"given":"Yufei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shansen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1943-3377","authenticated-orcid":false,"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpet.2026.105025_bib1","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"10.1016\/j.jpet.2026.105025_bib2","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jpet.2026.105025_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.jpet.2026.105025_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"10063","key":"10.1016\/j.jpet.2026.105025_bib5","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jpet.2026.105025_bib6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.23.02112","article-title":"US Food and Drug Administration approval summary: elacestrant for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer","volume":"42","author":"Shah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jpet.2026.105025_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.jpet.2026.105025_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.jpet.2026.105025_bib9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA Breast Cancer Study","volume":"42","author":"Martin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jpet.2026.105025_bib10","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (Giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.jpet.2026.105025_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","article-title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","volume":"24","author":"Hurvitz","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jpet.2026.105025_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","article-title":"Phase Ia\/b study of giredestrant \u00b1 palbociclib and \u00b1 luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced\/metastatic breast cancer","volume":"30","author":"Jhaveri","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.105025_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.annonc.2025.11.018","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase 3 EMBER-3 trial","volume":"37","author":"Jhaveri","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jpet.2026.105025_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100602","article-title":"Oral SERDs: transforming the treatment of advanced breast cancer-insights from EMBER-3","volume":"6","author":"Alva-Bianchi","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.105025_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13058-023-01695-4","article-title":"SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models","volume":"25","author":"Zhou","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.jpet.2026.105025_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41571-023-00853-z","article-title":"Optimizing the FDA's project optimus: opportunities and challenges","volume":"21","author":"Rodney","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.jpet.2026.105025_bib17","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology - when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.jpet.2026.105025_bib19","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Fourie Zirkelbach","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105025_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/psp4.12130","article-title":"Translational pharmacokinetic\/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab","volume":"6","author":"Lindauer","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.jpet.2026.105025_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/psp4.12196","article-title":"Advanced methods for dose and regimen finding during drug development: summary of the EMA\/EFPIA workshop on dose finding (London 4\u20135 December 2014)","volume":"6","author":"Musuamba","year":"2017","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.105025_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","article-title":"Handling data below the limit of quantification in mixed effect models","volume":"11","author":"Bergstrand","year":"2009","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.jpet.2026.105025_bib23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jps.23452","article-title":"Correlation of tissue-plasma partition coefficients between normal tissues and subcutaneous xenografts of human tumor cell lines in mouse as a prediction tool of drug penetration in tumors","volume":"102","author":"Poulin","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpet.2026.105025_bib24","author":"Beal"},{"issue":"2","key":"10.1016\/j.jpet.2026.105025_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"10.1016\/j.jpet.2026.105025_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.jpet.2026.105025_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048372","article-title":"Tumor volume as an alternative response measurement for imatinib treated GIST patients","volume":"7","author":"Schiavon","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jpet.2026.105025_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ejrad.2015.12.019","article-title":"Comparison of CT volumetric measurement with RECIST response in patients with lung cancer","volume":"85","author":"Hayes","year":"2016","journal-title":"Eur J Radiol"},{"issue":"16_Suppl","key":"10.1016\/j.jpet.2026.105025_bib29","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1158\/1538-7445.AM2020-4369","article-title":"Abstract 4369: preclinical mechanistic PK\/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development","volume":"80","author":"Gutierrez","year":"2020","journal-title":"Cancer Res"},{"issue":"16_Supplement","key":"10.1016\/j.jpet.2026.105025_bib30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1538-7445.AM2020-1042","article-title":"Abstract 1042: preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833","volume":"80","author":"Gangl","year":"2020","journal-title":"Cancer Res"},{"issue":"Suppl_4","key":"10.1016\/j.jpet.2026.105025_bib31","first-page":"S11","article-title":"Updated data from SERENA-1: a phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"81","author":"Baird","year":"2021","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jpet.2026.105025_bib32","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.3263","article-title":"Moving the needle for oncology dose optimization: a call for action","volume":"115","author":"Venkatakrishnan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jpet.2026.105025_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","article-title":"Application of Bayesian approaches in drug development: starting a virtuous cycle","volume":"22","author":"Ruberg","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"10.1016\/j.jpet.2026.105025_bib34","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jpet.2026.105025_bib35","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.105025_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.105025_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.jpet.2026.105025_bib38","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jpet.2026.105025_bib39","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15_Suppl","key":"10.1016\/j.jpet.2026.105025_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1101","article-title":"SERENA-4: a phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease","volume":"39","author":"Im","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:18:20Z","timestamp":1794561500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526012255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022356526012255"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105025","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational pharmacokinetic\/pharmacodynamic modeling to inform target concentration and dose projection of a novel selective estrogen receptor degrader (SIM0270) for early clinical development","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105025"}}